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Abstract
Background and Objective Schizophrenia is a low-prevalence mental disorder with a global age-standardized prevalence of 
21 million people (2016). Second-generation antipsychotics (lurasidone and quetiapine XR) are recommended as the first-
line treatment for schizophrenia. It is interesting to investigate how the results of clinical studies translate into direct medi-
cal costs. The objective of this analysis was to assess the direct medical costs related to pharmaceutical treatments and the 
management of relapses in patients affected with schizophrenia treated with lurasidone (74 mg) vs quetiapine XR (300 mg) 
assuming the Italian and Spanish National Health Service perspective.
Methods A health economic model was developed based on a previously published model. The analysis considered direct 
medical costs related to the pharmacological therapies and inpatient or outpatient management of relapses (direct medical 
costs referred to 2019). The probability of relapses and related costs were derived from two systematic reviews. A determin-
istic sensitivity analysis was implemented to test the robustness of the results.
Results The use of lurasidone (74 mg) compared with quetiapine XR (300 mg) would lead to a reduction in direct medical 
costs in Italy and Spain, with a lower cost per patient of − 163.7 € (− 9.0%) and − 327.2 € (− 22.7%), respectively. In detail, 
it would lead to an increase in the cost of therapy of + 53.8% and of + 30.5% in Italy and Spain, respectively, to a decrease 
in the cost of relapses with hospitalization of − 135.7%, and to an increase in the cost of relapses without hospitalization 
of + 24.5%.
Conclusions The use of lurasidone (74 mg) for the treatment of patients affected with schizophrenia, compared with quetia-
pine XR (300 mg), would be a cost-saving strategy in the two contexts investigated assuming the National Health Service 
point of view.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 1-020-00944 -0) contains 
supplementary material, which is available to authorized users.
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1  Background
Schizophrenia is a low-prevalence mental disorder, having 
a global age-standardized prevalence of 0.28% (95% uncer-
tainty interval 0.24–0.31) in 2016, which consists of 21 mil-
lion people globally affected [1]. In Europe in 2011, the 
median prevalence of the pathology, which tends to become 
chronic, was 1.2%, consisting of 5 million persons [2]. The 
prevalence of this mental disorder is different among age 
groups. This leads to a significant economic impact in terms 
of a loss of productivity of individuals and family members, 
as the group most affected by schizophrenia is the working 
age population.
Schizophrenia can be treated with conventional antipsy-
chotics, introduced from the 1950s onwards, and atypical 
antipsychotics, from the 1990s onwards, with a higher dem-
onstrated efficacy compared with conventional antipsychot-
ics [3, 4].
Schizophrenia has a significant impact in terms of direct 
and indirect costs, for patients, caregivers, and society [5]. In 
USA in 2011, compared with other mental disorders, schizo-
phrenia registered the second-longest average length of stay 
and the highest aggregate cost of hospitalization, which are 
attributable for 52% to indirect costs, 36% to direct health-
care costs, and 12% to direct non-healthcare costs [5]. In 
Europe, from a review published in 2018, the direct cost 
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Key Points 
The use of lurasidone (74 mg) compared with quetiapine 
XR (300 mg) for the treatment of patients affected with 
schizophrenia would lead to a reduction in the direct 
medical costs related to the management of patients for 
the Italian and Spanish National Health Service, mainly 
owing to a reduction in relapses requiring hospitaliza-
tion.
The reduction in relapses requiring inpatient manage-
ment would lead to positive organizational consequences 
for hospitals.
have similar efficacy, but different pharmacological profiles. 
When comparing patients with schizophrenia treated with 
lurasidone and quetiapine XR, it has been shown that those 
treated for 12 months with lurasidone had a statistically sig-
nificantly reduced risk of hospitalization [11]. It is interest-
ing to investigate how the results of clinical studies translate 
into direct medical costs.
Lurasidone is a second-generation antipsychotic that 
received a marketing authorization valid throughout the 
European Union by the European Medicines Agency on the 
20 March, 2014, and is indicated for the treatment of schizo-
phrenia in adults aged 18 years and over [12]. Lurasidone is 
a dopamine  D2 and serotonin 5-HT2A receptor antagonist, in 
addition, it has distinctive 5-HT7 antagonistic activity and 
partial agonism at 5-HT1A [13].
Quetiapine XR received a market authorization valid 
throughout the European Union on the 26 August, 2010 
and among its treatment indications there is “treatment of 
schizophrenia” [14]. It has a moderate affinity for 5-HT2A, 
α1, M1, and H1 receptors, and only a minor affinity for  D2 
and 5-HT1A receptors [15].
The objective of our analysis is to fill the gap in the 
literature related to the absence of direct comparisons of 
these two antipsychotics from an economic perspective at 
a European level by assessing the direct medical costs of 
relapse management in patients affected with schizophre-
nia, and accounting for the different likelihood of experi-
encing relapses under different treatments. The goal is to 
determine whether there is evidence of economic savings for 
the National Health Service of Italy or Spain (both south-
ern European universal systems) from the use of lurasidone 
(74 mg) compared to quetiapine XR (300 mg), which might 
result in health policy implications.
2  Methods
2.1  Model Design
A health economic model was developed using Microsoft 
Excel 2010 with the purpose of estimating the economic 
impact of relapses assuming the perspective of the National 
Health Service of Italy and Spain for patients with schizo-
phrenia treated with lurasidone vs quetiapine XR. Starting 
from the model schematization described by Rajagopalan 
et al. [5], a deterministic decision tree model was imple-
mented with a 1-year time horizon. A schematization of the 
model is reported in Fig. 1. The inputs considered in the 
model are the target population (eligible for treatment), clini-
cal and economic data concerning relapses (i.e., hospitaliza-
tions and outpatient treatment), defined daily doses, and the 
cost of each treatment (cost of drugs).
per patient is between a maximum of 13,704 € in the Neth-
erlands and a minimum of 533 € in Ukraine, with a major 
contribution attributable to inpatient costs and 25% of costs 
attributable to drugs [2].
Furthermore, in a recent Spanish study, analyzing the 
direct and indirect costs in a first episode of psychoses 
intervention program, the main findings were that the total 
costs during the first year of treatment after a first break of 
psychosis, on average per patient, were 48,354 €, with direct 
healthcare costs of 13,729 €, direct non-medical costs of 
109 €, and indirect costs of 34,515 €, the latter representing 
71.39% of the total cost [6].
A few studies in the literature have provided a cost-effec-
tiveness analysis for patients with schizophrenia in Spain, 
one of the countries of interest in this investigation. For 
instance, Olivares et al. [7] examined the impact of switch-
ing a previous antipsychotic to long-acting injectable risp-
eridone and Gutiérrez-Recacha et al. [8] focused on seven 
different types of clinical interventions at the level of the 
Spanish population. However, recently, to the best of our 
knowledge, neither Spain nor Italy has addressed the impact 
of one of the key and most significant drivers of direct medi-
cal and indirect costs in patients affected with schizophre-
nia—relapses. The choice of treatment for patients with 
schizophrenia may affect the likelihood of relapse. Differ-
ent atypical antipsychotics can prevent or delay relapses in 
patients with schizophrenia [9] improving clinical outcomes, 
and leading to economic savings and to a more efficient allo-
cation of resources from the societal perspective.
Antipsychotics, in particular second-generation antip-
sychotics, are recommended as the first-line treatment for 
schizophrenia [10]. Antipsychotics have been found to be a 
heterogeneous class of drugs with varied efficacy and toler-
ability profiles. Lurasidone and quetiapine XR, both are clas-
sified as second-generation antipsychotics. These two drugs 
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2.2  Target Population
The target population of the analysis consists of adult indi-
viduals affected with schizophrenia treated with antipsy-
chotics. The population considered does not reflect the real 
number of patients who will be treated with lurasidone or 
quetiapine XR in each national context, but the result will 
approximate the potential impact of the use of lurasidone in 
the case where all eligible patients are treated with lurasi-
done, compared with quetiapine XR. To estimate this popu-
lation, the overall number of patients affected with schizo-
phrenia in each context was considered. This is owing to the 
fact that a treated pediatric population is negligible in terms 
of numbers of patients, and that it would not be possible to 
estimate the number of patients not eligible to use the drugs 
for metabolic or other reasons because of a lack of available 
literature data. Furthermore, because of the stability of the 
prevalence of schizophrenia over the years, data referred to 
years before 2019 were considered as representative of 2019.
In Italy, the target population was estimated consider-
ing the prevalence of treated patients affected with schizo-
phrenia and other functional psychoses [16], being 35.8 per 
10,000 inhabitants in 2017. Based on the Italian resident 
population (60,359,546) on 1 January, 2019, as reported by 
Eurostat (2019) [17], the target population was estimated in 
216,087 patients.
In Spain, the number of patients affected by schizophrenia 
is estimated to be equal to 400,000 [18]. Lacro and col-
leagues report that the mean non-adherence rate in patients 
with schizophrenia is 49.5% [19]. Considering that 50.5% 
of population is adherent to pharmacological therapies, the 
estimated number of patients considered in the analysis for 
the Spanish context is 202,000.
2.3  Probability of Relapse
To estimate the probability of relapse in individuals with 
schizophrenia receiving treatment with lurasidone or que-
tiapine XR, a systematic literature review was conducted 
through PubMed. In accordance with PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analy-
ses) guidelines, the process was divided into four stages: 
identification, screening, eligibility, and inclusion [20]. 
Concerning the identification stage, the keywords used 
for this search were: (“lurasidone” OR “quetiapine XR”) 
“schizophrenia”. The resulting search string was: ((“lurasi-
done hydrochloride”[MeSH Terms] OR (“lurasidone”[All 
Fields] AND “hydrochloride”[All Fields]) OR “lurasidone 
hydrochloride”[All Fields] OR “lurasidone”[All Fields]) OR 
((“quetiapine fumarate”[MeSH Terms] OR (“quetiapine”[All 
Fields] AND “fumarate”[All Fields]) OR “quetiapine 
fumarate”[All Fields] OR “quetiapine”[All Fields]) AND 
XR[All Fields])) AND (“schizophrenia”[MeSH Terms] OR 
“schizophrenia”[All Fields]).
To assess the probability of relapse, the eligibility criteria 
to identify the articles were: reference to the pathology of 
interest (schizophrenia), include at least one of the contexts 
of interest (Italy or Spain), and include a direct compari-
son of the two drugs included in the analysis (quetiapine 
XR or lurasidone). The search identified 240 documents. 
In accordance with the screening stage, 223 documents 
were excluded, not being pertinent to the subject or because 
written in languages other than English, Italian, or Spanish. 











Fig. 1  Schematization of the model
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Using a single database, it was not necessary to remove 
duplicates.
For the eligibility stage, two independent researchers 
reviewed the results, after the reading of the abstracts, six 
articles were excluded because they did not compare the two 
selected drugs. Of the 11 remaining articles, after reading 
the entire manuscripts, six of them were excluded because 
they did not consider relapses as an outcome measure, three 
because they did not compare directly the two drugs, and 
one was excluded because the results presented were already 
included in a more recent publication. Concerning the inclu-
sion stage, only one article was considered as pertinent with 
the review. A schematization of the research performed is 
reported in Fig. 2.
The selected study, a 12-month double-blind non-infe-
riority study, published by Loebel et al. [11], assessed the 
non-inferiority of flexibly-dosed lurasidone (37–148 mg/
day) compared with quetiapine XR (200–800 mg/day) in 
terms of relapse prevention, in a 12-month period, in adult 
patients with chronic schizophrenia who completed a previ-
ous 6-week placebo-controlled trial. Relapse was defined 
as the occurrence of one criterion between: worsening of 
30% or more in the Positive and Negative Syndrome Scale 
total score from day 42 from short-term treatment and Clini-
cal Global Impression Scale-Severity of Illness score ≥ 3, 
re-hospitalization or aggravation of psychosis, emergency 
related to suicidal or homicidal ideation, or risk of harm. 
Results showed that lurasidone had a 23.7% probability 
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Fig. 2  PRISMA flow diagram of literature review to estimate the probability of relapse  in individuals with schizophrenia receiving treatment 
with lurasidone or quetiapine XR
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of relapse and quetiapine XR had a 33.6% probability of 
relapse, at 12 months, with a 27.2% reduction in relapse risk 
for lurasidone, which demonstrated non-inferiority in time to 
relapse and probability of relapse. Furthermore, lurasidone 
showed a significantly lower probability of hospitalization 
at 12 months compared with quetiapine XR (9.8% vs 23.1%; 
p < 0.05).
The probability of relapses managed in inpatients at 
12 months was considered as the probability of hospitaliza-
tion at 12 months, while the probability of relapses managed 
in outpatients at 12 months was derived as the difference of 
the probability of relapse at 12 months and of the probabil-
ity of hospitalization at 12 months. Data related to relapses 
probability are reported in Table 1.
2.4  Direct Medical Costs
The costs considered in the analysis are direct medical 
costs related to the cost of antipsychotics and to the cost 
of relapses. To assess the direct medical costs related to 
relapses, a systematic literature review was conducted in 
accordance with PRISMA guidelines [20]. The identifica-
tion stage was conducted using the following keywords on 
the search engine PubMed: “cost” and “schizophrenia” and 
the resulting search string was: ((“economics”[Subheading] 
OR “economics”[All Fields] OR “cost”[All Fields] OR 
“costs and cost analysis”[MeSH Terms] OR (“costs”[All 
Fields] AND “cost”[All Fields] AND “analysis”[All 
Fields]) OR “costs and cost analysis”[All Fields]) AND 
(“schizophrenia”[MeSH Terms] OR “schizophrenia”[All 
Fields])).
To assess direct medical cost related to relapses the eli-
gibility criteria to identify the articles were: reference to the 
pathology of interest (schizophrenia), include at least one of 
the contexts of interest (Italy or Spain) and include quantita-
tive data of direct health costs related to relapses. Two hun-
dred and fifty-six articles were found, of which 222 articles 
were excluded from reading the title during the screening 
stage, not being pertinent to the topic, or not being written in 
any of the three languages considered (as explained above). 
The eligibility stage was conducted starting from the read-
ing of the abstract, after which 19 articles were excluded as 
they did not report economic analysis conducted in either 
of the countries considered: Italy and Spain. Of the remain-
ing 15 articles, after a thorough reading, four relevant docu-
ments were considered, excluding 11 articles because the 
costs related to the disease were not assessed, neither were 
the relapses considered in the analysis. Looking carefully 
into the details, two articles reported an average cost at a 
European level, six of them were not focused on the topic of 
interest, and three studies did not consider relapses.
Moreover, after an analysis of the four relevant stud-
ies identified, three documents were excluded because of 
the lack of an explicit economic evaluation of relapses. In 
detail, the overall costs related to patient management were 
reported, not providing details on the cost of relapses. Dur-
ing the inclusion stage, one article was selected as pertinent 
to the review. A schematization of the literature review is 
reported in Fig. 3.
The article selected is the analysis conducted by Dilla 
and colleagues that compared the costs associated with 
the two therapies, among which neither lurasidone nor 
quetiapine XR was considered [21]. The cost of relapse 
has been obtained from a cost-effectiveness study that 
estimated the value over a 5-year period adopting the 
point of view of the Spanish National Health Service. 
The study reports inpatient and outpatient costs of relapse 
management referred to year 2011 (original data referred 
to year 2000). Data were obtained from a retrospective 
review with 200 records of patients from eight Spanish 
hospitals that considered fixed costs (medical, nursing, 
and other staff, room and catering, allocated common 
services costs, and other services), diagnostic tests, and 
drug treatment [22]. The results showed costs associated 
with relapse management for the Spanish Healthcare Ser-
vice of 4226.91 € for inpatient activities and 884.38 € for 
outpatient activities, assuming hospitalization as a proxy 
for relapse.
Because of the lack of results concerning the issue of 
the economic impact of relapses in Italy, a further litera-
ture review was performed. The research focused on peer-
reviewed health economics journals related to the Italian 
context, in details: Clinico Economics—Italian Articles 
on Outcomes Research, Italian Journal of Public Health, 
Global & Regional Health Technology Assessment—Ital-
ian, Farmeconomia—Health Economics and Therapeutic 
Table 1  Clinical data: hospitalization and relapses
a Calculated as the difference of the probability of relapse at 12 months and of the probability of hospitalization at 12 months
Lurasidone (%) Quetiapine XR (%) Reference
Probability of relapse at 12 months 23.70 33.60 Loebel et al. [11]
Probability of hospitalization at 12 months 9.80 23.10 Loebel et al. [11]
Probability of relapse managed in an outpatient setting at 
12 months
13.90a 10.50a
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Pathways. The research identified an additional article 
reporting costs associated with schizophrenia, in particu-
lar related to the event of relapse, in the Italian context.
Berto et al. evaluated with a cost-effectiveness analy-
sis the effects of schizophrenia in monetary terms from 
the perspective of the Italian National Health Service in 
a 52-week time horizon [23]. The analysis reports the 
cost of relapses with and without hospitalization related 
to five different drugs; however, the document does 
not report details on the calculation method. The mean 
weighted cost of relapses with hospitalization is 4749.25 
€ and 1908.04 € without hospitalization.
The cost of relapses in each arm was calculated using 
the probabilities of relapse at 12 months and the costs of 
the management in the two countries for which they are 
available, inflated at year 2019 using an inflation percent-
age change relative to average consumer prices [24]. It 
is important to underline the fact that the cost of relapse 
management in Italy and Spain might have changed since 
the date of publication of the analyses published in the 
literature (before 2010). However, the uncertainty over 
this aspect has been managed in the sensitivity analysis.
The annual cost of lurasidone and quetiapine XR con-
sidered is the price to the public. The posology considered 
in the analysis is 74 mg for lurasidone and the equivalent 
dose of quetiapine XR of 300 mg, as reported by Leucht 
and colleagues [25]. Costs considered in the analysis are 
summarized in Table 2 (i.e., cost per relapse, and cost per 
tablet and mean annual cost per patient).
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Fig. 3  PRISMA flow diagram of literature review to assess the direct medical costs related to relapses in individuals with schizophrenia
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2.5  Sensitivity Analysis
A sensitivity analysis was conducted varying the follow-
ing parameters: probability of relapses managed with a 
hospitalization − 20% (to represent the different clinical 
approach in the management of relapses in previous years 
compared with the year of the publication of Loebel and 
colleagues), ± 20% of the cost of relapses, ± 10% of the 
cost of lurasidone, and − 40% of the target population.
3  Results
The results of the analysis, in terms of cost per therapy, relapse 
with hospitalization, and relapse without hospitalization are 
presented in Table 3. The use of lurasidone (74 mg) compared 
with quetiapine XR (300 mg) would lead to a reduction in 
direct medical costs in Italy and Spain, with a lower cost per 
patient of − 163.7 € and − 327.2 €, respectively. The highest 
impact on total cost is related to the cost of the therapy in both 
contexts. Concerning the Italian context, the cost of therapy 
with lurasidone (74 mg) compared to quetiapine XR (300 mg) 
registered an increase of 109,930,325 € (+ 53.8%), the cost 
of relapses with hospitalization a decrease of − 161,741,917 
(− 135.7%), and the cost of relapses without hospitalization an 
increase of 16,456,757 € (+ 24.5%) with a total cost reduction 
of − 35,364,834 (− 9.0%). In the Spanish context, the use of 
lurasidone (74 mg) compared with quetiapine XR (300 mg) 
is associated with an increase of 52,350,055 € (+ 30.5%) 
of the cost of therapy, with a decrease of − 125,132,927 € 
(− 135.7%) of the cost of relapses with hospitalization, and 
with an increase of 6,692,908 € (+ 24.5%) of the cost of 
relapses without hospitalization, with a total cost reduction of 
− 66,089,974 (− 22.7%).
The results of the sensitivity analysis (reported in Table 4 
and in Figs. 4, 5) show a lower and maximum total cost dif-
ference of − 1.8% and − 15.0% in Italy and of − 15.9% and 
− 28.5% in Spain. In both contexts, the scenario that leads 
to a lower cost difference is the scenario that considers a cost 
per-relapse reduction of − 20%, while the scenario that leads 
to the wider cost difference is the scenario that considers an 
increase of the cost of relapses of + 20%.  
4  Discussion
The results of the analysis presented show a reduction in 
annual per capita direct medical costs related to the use of 
lurasidone (74 mg) compared with quetiapine XR (300 mg) 
both in Italy and Spain equal to − 163.7 € and − 327.2 €, 
respectively. The sensitivity analysis confirmed the robust-
ness of the results.
The model used in the analysis is an adaptation of that 
implemented by Rajagopalan and colleagues, who investi-
gated the financial impact on schizophrenia-related relapses 
of the use of lurasidone vs quetiapine XR in the US context 
[5]. The analysis conducted in this context showed a wider 
difference related to the higher cost per hospitalization com-
pared with the present analysis. Lurasidone would have led 
Table 2  Costs considered in the analysis (2019 value)
Italy (€) Spain 
(€)
Cost of relapse management with 
hospitalization
5628.2 4657.7




 Price per tablet (74 mg) 2.59 2.33
 Annual cost per patient 946.00 850.58
Quetiapine XR
 Price per tablet (300 mg) 1.20 1.62
 Annual cost per patient 437.27 591.42
Table 3  Results of the analysis
Context Cost category Lurasidone (€) Quetiapine XR (€) ∆ (€)
Italy Therapy 204,418,688 94,488,362 + 109,930,325
Relapse with hospitalization 119,185,623 280,937,539 − 161,751,917
Relapse without hospitalization 67,279,095 50,822,338 + 16,456,757
Total cost 390,883,406 426,248,240 − 35,364,834
Cost per patient 1808.9 1972.6 − 163.7
Spain Therapy 171,817,232 119,467,177 + 52,350,055
Relapse with hospitalization 92,203,217 217,336,154 − 125,132,937
Relapse without hospitalization 27,362,181 20,669,273 + 6,692,908
Total cost 291,382,630 357,472,603 − 66,089,974
Cost per patient 1442.5 1769.7 − 327.2
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to a reduction in costs of US$ − 3276 per patient compared 
with quetiapine XR.
There are limitations to our analysis. The quantification 
of direct medical costs related to relapses is based on the 
most recent analyses conducted in the two contexts investi-
gated, published before 2010. The clinical practice in terms 
of relapse management may have changed over the years. 
The uncertainty over this aspect has been managed in the 
sensitivity analysis, showing a limited impact on the differ-
ential cost between the two scenarios. Furthermore, the tar-
get population considered in the analysis does not reflect the 
real number of patients who will be treated with lurasidone 
or quetiapine XR in each national context, but the results 
approximate the potential impact of the use of lurasidone in 
the case where all eligible patients are treated with lurasi-
done, compared with quetiapine XR.
The main strength of the analysis is related to the use 
of clinical inputs derived from a direct comparison of lur-
asidone and quetiapine XR. In detail, the probability of 
relapse at 12 months (33.6% for quetiapine XR and 23.7% 
for lurasidone) and the probability of hospitalization at 
12 months (23.1% for quetiapine XR and 9.8% for lurasi-
done) were derived from the analysis published by Loebel 
and colleagues [11], while the probability of relapse man-
aged in an outpatient setting at 12 months was calculated as 
the difference of the aforementioned probabilities (10.5% for 
quetiapine XR and 11.9% for lurasidone).
The relevance of our article stems from the fact that there 
is a lack of studies relating to the economic impact of differ-
ent treatments for patients affected with schizophrenia and 
their relapses in countries with a National Health Service 
such as Italy or Spain, taking into account the management 
of the relapse with or without hospitalization. We provide a 
piece of research to fill this gap in the literature. Our finding 
shows that the use of lurasidone (74 mg) for the treatment 
of patients affected with schizophrenia, compared with que-
tiapine XR (300 mg), would be a cost-saving strategy in 
the two contexts investigated assuming the National Health 
Service point of view. Our literature review has only found 
a few publications with useful information on that aim, 
and these are considerably old. As a consequence, further 
research is needed on this topic.
Table 4  Results of the sensitivity analysis
Context Scenario Cost Lurasidone (€) Quetiapine XR (€) ∆ (€)
Italy Probability of relapses managed 
with a hospitalization − 20%
Total cost 376,533,118 392,422,561 − 15,889,443
Cost per patient 1742.5 1816.0 − 73.5
Cost of relapses + 20% Total cost 428,176,349 492,600,215 − 64,423,866
Cost per patient 1981.5 2279.6 − 298.1
Cost of relapses − 20% Total cost 353,590,462 359,896,264 − 6305,802
Cost per patient 1636.3 1665.5 − 29.2
Cost of lurasidone + 10% Total cost 411,325,274 426,248,240 − 14,922,965
Cost per patient 1903.5 1972.6 − 69.1
Cost of lurasidone − 10% Total cost 370,441,537 426,248,240 − 55,806,703
Cost per patient 1714.3 1972.6 − 258.3
Target population − 40% Total cost 234,530,043 255,748,944 − 21,218,900
Cost per patient 1808.9 1972.6 − 163.7
Spain Probability of relapses managed 
with a hospitalization − 20%
Total cost 276,800,251 323,099,853 − 46,299,602
Cost per patient 1370.3 1599.5 − 229.2
Cost of relapses + 20% Total cost 315,295,709 405,073,689 − 89,777,980
Cost per patient 1560.9 2005.3 − 444.4
Cost of relapses − 20% Total cost 267,469,550 309,871,518 − 42,401,968
Cost per patient 1324.1 1534.0 − 209.9
Cost of lurasidone + 10% Total cost 308,564,353 357,472,603 − 48,908,251
Cost per patient 1527.5 1769.7 − 242.1
Cost of lurasidone − 10% Total cost 274,635,509 357,472,603 − 83,271,697
Cost per patient 1357.4 1769.7 − 412.2
Target population − 40% Total cost 174,829,578 214,483,562 − 39,653,984
Cost per patient 1442.5 1769.7 − 327.2
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5  Conclusions
This article presents an analysis in which we show a reduc-
tion in terms of direct medical costs related to the use of 
lurasidone (74 mg) compared with quetiapine XR (300 mg) 
in a 1-year time horizon, assuming the point of view of the 
National Health Service in Italy and Spain. We use the fact 
that the main cost driver for patients affected with schizo-
phrenia is the probability of experiencing relapses, and our 
Fig. 4  Tornado diagram related 
to the Italian context
Fig. 5  Tornado diagram related 
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analysis is based on the study of the cost of relapses for 
patients following both treatments. The use of lurasidone 
compared with quetiapine XR leads to a decrease in relapses 
with hospitalization in adult patients affected with schizo-
phrenia and the related costs, and to an increase in costs 
related to relapses without hospitalization and therapy costs. 
The results show an annual reduction in direct medical costs 
per patient associated with the use of lurasidone of − 163.7 € 
(with a reduction of − 35.4 € million considering the eligible 
population; − 9.0%) in Italy and − 327.2 € (with a reduc-
tion of − 66.1 € million considering the eligible population; 
− 22.7%) in Spain.
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